Short-term Priorities for Antiretroviral Drug Optimization

The World Health Organization (WHO), with support from the Pangaea Global AIDS Foundation and funding from the Bill & Melinda Gates Foundation, convened a meeting of experts in HIV treatment from around the world to establish short-term treatment optimization priorities for preferred first- and second-line regimens recommended in 2010 WHO guidelines for adults and paediatrics. The list of attendees is attached at Annex A.

For this meeting, short-term drug optimization was defined as a three-year window (2011-2013), and discussion focused on preferred first- and second-line regimens for adults and paediatrics recommended in the 2010 WHO Guidelines.

The meeting’s objective was to refine the recommendations of the Conference on Anti-Retroviral Drug Optimization (CADO) held in June, 2010, and the recommendations made by the Medicines Patent Pool, UNITAID and WHO, endorsed by a number of global partners working on the Treatment 2.0 initiative, to the WHO Expert Committee on Essential Medicines in March, 2011.